Patient and physician preferences for ulcerative colitis treatments in the United States

Marco Boeri1 RTI Health Solutions, Health Preference Assessment, Belfast, BT2 8LA, UKCorrespondence[email protected]

Kelley Myers2 RTI Health Solutions, Health Preference Assessment, Research Triangle Park, NC, 27709, USA

Claire Ervin2 RTI Health Solutions, Health Preference Assessment, Research Triangle Park, NC, 27709, USA

Amy Marren3 Pfizer, Inflammation and Immunology, Collegeville, PA, 19426, USA

Marco DiBonaventura4 Pfizer, Health Economics and Outcomes Research, New York, NY, 10017, USA

Joseph C Cappelleri5 Pfizer, Global Product Development, Groton, CT, 06340, USA

Brett Hauber2 RTI Health Solutions, Health Preference Assessment, Research Triangle Park, NC, 27709, USA

David T Rubin6 Department of Medicine, Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL60637, USA

Your download is now in progress and you may close this window